Abstrak
Helicobacter pylori (H. pylori) can infect the stomach during childhood and cause chronic gastritis leading to peptic ulcer. 1 This infection is also classifi ed as a class 1 stomach carcinogen.
2 More than 50% of the population of western countries suffer from this infection and 80-90% of the population of developing countries has at some time been infected by this bacterium. 3 Re-infection is rare in adults because the treatment results in permanent eradication of the infection, thus preventing further complications such as peptic ulcer, which can lead to perforation and bleeding, and also in turn leading to raising the general standard of health 4 At present, there is still no standard composition or duration for the therapeutic regimen, because suffi cient research to establish the most effective regimen has not yet been carried out. At present, a combination of three drugs is used: a proton pump inhibitor (PPI) with any two of the antibiotics amoxicillin, clarithromycin, metronidazole or trinidazole. This achieves a bacterial eradication rate of greater than 85%.
A combination of PPI and 1000 mg amoxicillin/500 mg clarithromycin twice a day has been proven effective in the eradication of H. pylori. 5 Most studies have used all three drugs twice daily for 2 weeks. Other trials in the Asian region have suggested that treatment for a shorter period of time, 7-10 days, may be nearly as effective.
6 To the present, only a few studies that have used triple therapy for a short time (5 days). If this is as effective as 7 days triple therapy, this shorter therapy could be used for patients in developing countries such as Indonesia.
The objective of this study was to compare 5-day and 7-day rabeprazole triple therapy for eradication of H. pylori infection.
METHODS
This was a multicentre, randomized controlled trial that included six centres in Indonesia: Jakarta, Bandung, Jogjakarta, Surabaya, Medan and Denpasar. Five centres in Indonesia recruited six or more patients. Patients with H. pylori infection were included in this study. The following criteria applied to the patients to be admitted to the study: signed informed consent, positive for H. pylori with two positive test results from the rapid urea test (Pronto Dry) and positive for histology or urea breath test (UBT), aged over 18.
The patients did not use antibiotics or proton pump inhibitors (PPI) for 1 week before the study. Patients who had an allergy to amoxicillin or clarithromycin or a history of severe liver disease and renal failure and any signifi cant symptoms such as weight loss, gastrointestinal bleeding, jaundice or other serious disease were excluded. We also excluded pregnant and lactating women.
All patients fulfi lling the requirements underwent endoscopy. At endoscopy, evaluation of two antral and two corpus biopsy specimens were obtained. One biopsy from the antrum and one biopsy from the corpus were used for the Pronto Dry test and the others were used for histological examination. Specimens for histology were stained with haematoxylin and eosin. An experienced gastrointestinal pathologist reviewed all specimens.
Histopathological examination
Biopsy specimens for histopathological examination were fi xed in buffered 4% formalin overnight and embedded in paraffi n. Two 4 mm sections were stained with haemotoxylin-eosin and one section was stained by the modifi ed Giemsa procedure. The slides were microscopically examined using high power and at least fi ve high-power fi elds were examined. If H. pylori was observed the bacterial density was scored semi-quantitatively on an ordinal scale (0-3) by a single pathologist. A single pathologist performed the histological evaluation of gastric mucus. Histology grades for H. pylori density, polymorphonuclear neutrophil activity, chronic infl ammation, glandular atrophy and intestinal metaplasia were classifi ed according to the updated Sydney System. Positive results for H. pylori were based on a positive result from either the rapid urease test or microscopic detection of H. pylori.
Study design and medication
Sixty H. pylori-infected patients were randomized to one of the following two groups:
Rabeprazole 10 mg/amoxicillin 1000 mg/clarithromycin -500 mg b.i.d for 7 days Rabeprazole 10 mg/amoxicillin 1000 mg/clarithromycin -500 mg b.i.d for 5 days During treatment, the patients assessed their upper gastrointestinal symptoms and use of medication on a diary card and returned all remaining medications at follow-up. We also noted the patients' complaints after treatment. Four weeks after treatment, a urea breath test was performed. The cure rate was defi ned as the number of successfully treated patients divided by the number of successfully treated plus the number of unsuccessfully treated patients. The cure rate was evaluated by per protocol analysis.
Statistical analyses
The result was analysed by a statistician. Univariate values were expressed as mean, standard deviation (SD), minimum and maximum. Bivariate analysis by independent t test to compare means and two-sided Fisher's exact test (c 2 ) with 95% confi dence interval (CI) were used to assess the signifi cant differences between values in the two groups of patients. A probability (p) value of less than 0.05 was considered signifi cant. Statistical analyses were conducted using SPSS version 16.
RESULTS
Of the 60 patients, consisting of 42 males (70%) and 18 females (30%) with mean age (± SD) 47.63 ± 13.93, range 21-74 years, 25 patients (41.7%) and 35 patients (58.3%) respectively completed 5-day and 7-day treatment (Table 1 ).
In the 5-day treatment group there were 15 males (60%) and 10 females (40%) aged (+SD) 47.44 ± 14.47 years, range 21-74 years, while in the 7-day treatment group there were 27 males (77.1%), 8 females (22.9%) aged 47.77 ± 13.74, range 22-74 years.
After treatment, H. pylori was eradicated in 18 patients (72%) given 5-day treatment and 32 patients (91.4%) given 7-day treatment, while eradication failure was founded on 7 patients (28.0%) in 5-day treatment and 3 patients (8.6%) in 7-day treatment. This eradication rate was based on per protocol analysis. (Table 2 ).
DISCUSSION
Even though many different therapeutic regimens have been studied for H. pylori eradication in acid-related disorders, 7,8 1-week PPI-based triple therapy has been widely accepted as the standard treatment of peptic ulcer with H. pylori infection. 9-11 However, the optimal duration of triple therapy remains to be established. More recently, many newer PPIs have been developed that possess the ability for potent and rapid inhibition of gastric acid secretion. 12,13 Therefore, short-term regimens (<7 days) have been suggested for the eradication of H. pylori infection.
A new PPI, rabeprazole, has been demonstrated to be effective in the treatment of acid-related disorders including peptic ulcer disease. [16] [17] [18] Rabeprazole rapidly and potently inhibits gastric acid secretion. In addition, this PPI can induce earlier stabilization of antibiotics and has a higher rate of eradication of H. pylori compared with other PPIs.
19,20
Several studies have compared the eradication rate of a short-term course with that of standard course rabeprazole-based triple therapy for H. pylori infection. In a study by Wang et al. 21 , the eradication rate decreased from 84.6% to 78.4% in the 3-day group and from 87.5% to 81.6% in the 7-day group tested between three months and 12 months after rabeprazole-based triple therapy.
Our study showed that a 5-day rabeprazole-based triple therapy regimen had lower eradication rates (72.0% vs. 91.4%, p = 0.077) against H. pylori infection compared with a 7-day rabeprazole-based triple therapy regimen. The non statistical signifi cance was likely due to small sample size.
The differences between our study and Wang's previous study are that we gave the drugs (amoxicillin 1000 mg, clarithromycin 500 mg and rabeprazole 10 mg) twice daily for 5 or 7 days, then evaluated at 4 weeks. In Wang et al.'s study they gave 20 mg rabeprazole twice in 3 days or 7 days. In the past, there have been concerns in many studies about antimicrobial resistance of H. pylori resulting from eradication therapy. 26,27 H. pylori clarithromycin resistance is the main factor impairing the effi cacy of standard triple therapy. H. pylori resistance against clarithromycin is increasing worldwide, but our data show that the success rate of 7-day triple therapy using clarithromycin is still good (91.4%).
The study showed that the eradication of H. pylori infection by triple rabeprazole-based treatment in 7-day is still better than in 5-day for peptic ulcer with H. pylori infection disease at the recent. However, more samples are needed for further evaluating the effectiveness between these 2 treatments.
